The imperative of affordable medicines
Access to affordable medicines remains one of the most urgent public health and economic challenges across many African countries. Medicines are the backbone of modern healthcare systems, yet millions of citizens across the continent struggle to obtain the essential drugs they need. When medicines are unaffordable, treatment is delayed, adherence declines, preventable illnesses escalate, and national productivity is weakened.
The issue before Africa is, therefore, not merely a pharmaceutical or economic problem—it is a humanitarian and developmental imperative. The challenge is clear: how can African nations reduce the cost of medicines while maintaining the highest standards of quality, safety, and innovation?
The answer lies in strategic cooperation across the three foundational pillars of the pharmaceutical ecosystem, industry, academia, and regulatory institutions, combined with deeper continental collaboration enabled by the African Continental Free Trade Area (AfCFTA).
When these actors operate in isolation, fragmentation and inefficiency emerge. When they work together, they can unlock transformative opportunities for Africa’s pharmaceutical future.
Understanding the structural drivers of high medicine costs
Before solutions can be effectively implemented, it is important to understand the structural factors driving the high cost of medicines across the continent.
Many African pharmaceutical markets are heavily dependent on imported raw materials, including active pharmaceutical ingredients (APIs), excipients, packaging materials, and manufacturing equipment. Currency volatility, logistics costs, and global supply chain disruptions therefore directly influence the price of medicines.
In addition, limited local manufacturing capacity, fragmented distribution systems, regulatory delays, and weak research–industry linkages contribute to inefficiencies that ultimately raise patient costs.
Furthermore, the lack of strong domestic innovation ecosystems means that many pharmaceutical companies depend on external technologies rather than locally developed solutions tailored to African health realities.
No single institution can solve these structural challenges. They require systemic collaboration and coordinated continental strategies.
The role of industry: Driving manufacturing efficiency and scale
The pharmaceutical industry sits at the centre of the medicine production ecosystem. Manufacturers must therefore continue to invest in local manufacturing capacity, operational efficiency, and supply chain optimisation.
African pharmaceutical companies must increasingly embrace process innovation, technology-transfer partnerships, and shared industrial infrastructure to reduce production costs while improving quality.
Industry associations can also collaborate to develop shared facilities such as pharmaceutical testing laboratories, formulation development centres, technology transfer hubs, and API manufacturing platforms. Such collaborative investments can significantly lower the structural cost of production.
Equally important is stronger engagement with academic institutions to ensure that scientific research translates into scalable pharmaceutical solutions.
The role of academia: Knowledge, innovation, and talent development
Universities and research institutions are the engines of scientific discovery and innovation. Their contribution to reducing the cost of medicines lies in research excellence, knowledge generation, and the development of highly skilled human capital.
Academic researchers can play a crucial role in developing cost-efficient formulations, improved drug-delivery systems, locally adaptable pharmaceutical technologies, and alternative sourcing strategies for raw materials.
However, research achieves its greatest value when it moves beyond the pages of academic journals into real-world industrial applications. Strong industry–academia partnerships ensure that discoveries in laboratories translate into affordable medicines in pharmacies.
Universities must therefore not only train pharmacists and pharmaceutical scientists but also cultivate professionals who understand the intersection of science, manufacturing, economics, and healthcare policy.
The role of regulatory bodies: Enabling efficiency without compromising safety
Regulatory agencies play a vital role in protecting public health by ensuring that medicines are safe, effective, and of high quality. At the same time, regulatory efficiency significantly influences the cost of bringing medicines to market.
Transparent regulatory frameworks, science-based guidelines, predictable approval timelines, and digital regulatory systems can greatly reduce the administrative and financial burden associated with product registration and market entry.
African regulatory authorities can also benefit from regulatory harmonisation initiatives, which reduce regulatory process duplication across countries and enable pharmaceutical products approved in one jurisdiction to move more efficiently across others.
Such reforms protect patients while encouraging pharmaceutical innovation, investment, and manufacturing growth.
AfCFTA: A Historic Opportunity for Continental Pharmaceutical Integration
The African Continental Free Trade Area (AfCFTA) provides a historic opportunity to transform Africa’s pharmaceutical ecosystem by enabling deeper regional cooperation, industrial integration, and market expansion.
By creating a unified continental market, AfCFTA allows African pharmaceutical manufacturers to scale production beyond national markets and serve a population of over 1.4 billion people. This scale is critical for reducing production costs and achieving manufacturing efficiency.
More importantly, AfCFTA creates the framework for cross-border collaboration among industry, universities, and regulators, enabling:
• Regional pharmaceutical manufacturing hubs
• Shared regulatory science and harmonised approval systems
• Cross-border research collaborations
• Integrated supply chains for APIs and pharmaceutical inputs
• Joint training and workforce development programmes
Such integration can significantly improve continental effectiveness, operational efficiency, and system agility in responding to health challenges.
Through AfCFTA, Africa can move from fragmented national pharmaceutical markets toward a coordinated continental health manufacturing ecosystem.
Building a collaborative pharmaceutical ecosystem
The experience of countries that have successfully developed strong pharmaceutical sectors—such as India, Brazil, and South Korea—shows that strategic collaboration between industry, academia, and regulators is the cornerstone of pharmaceutical competitiveness.
Africa can replicate and adapt these lessons by creating structured platforms that bring these stakeholders together for the following:
• Joint research and development programmes
• Technology transfer partnerships
• Workforce development initiatives
• Pharmaceutical innovation hubs
• Regulatory science collaborations
When these actors work together with a shared purpose, the cost of medicine production can fall while quality and innovation improve.
Towards pharmaceutical sovereignty in Africa
Reducing the cost of medicines is not merely an economic objective; it is also a matter of health security and continental resilience.
Countries that depend excessively on imported medicines remain vulnerable to global supply disruptions, currency instability, and geopolitical shocks.
Strengthening Africa’s pharmaceutical manufacturing, research capacity, and regulatory systems will move the continent closer to pharmaceutical sovereignty—the ability to produce essential medicines locally while maintaining global quality standards.
Achieving this vision will require bold leadership, long-term investment, and strong institutional cooperation.
A shared responsibility for Africa’s health future
No single institution can drive the journey toward affordable medicines in Africa. It requires a shared commitment from industry leaders, academic institutions, regulatory authorities, policymakers, and continental bodies.
When industry brings manufacturing expertise, academia contributes knowledge and innovation, regulators provide a stable enabling environment, and AfCFTA enables continental integration, Africa can build a resilient pharmaceutical ecosystem capable of delivering affordable medicines to its people.
If we succeed in building these bridges across institutions and across borders, we will achieve far more than lower medicine prices.
We will strengthen Africa’s health security, enhance economic resilience, empower scientific innovation, and improve the well-being of millions across the continent.
That is a vision worthy of Africa’s collective effort.
Prof Lere Baale: CEO – Business School Netherlands International – Nigeria
Join BusinessDay whatsapp Channel, to stay up to date
Open In Whatsapp
